-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Robert Benjamin Stein Sells 19,000 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock
Robert Benjamin Stein Sells 19,000 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock
MiMedx Group, Inc. (NASDAQ:MDXG – Get Rating) insider Robert Benjamin Stein sold 19,000 shares of the company's stock in a transaction on Monday, September 12th. The stock was sold at an average price of $3.44, for a total transaction of $65,360.00. Following the completion of the sale, the insider now owns 287,002 shares of the company's stock, valued at $987,286.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Robert Benjamin Stein also recently made the following trade(s):
Get MiMedx Group alerts:- On Friday, August 12th, Robert Benjamin Stein sold 8,503 shares of MiMedx Group stock. The stock was sold at an average price of $4.04, for a total transaction of $34,352.12.
- On Thursday, August 4th, Robert Benjamin Stein sold 19,500 shares of MiMedx Group stock. The stock was sold at an average price of $3.62, for a total transaction of $70,590.00.
- On Tuesday, June 28th, Robert Benjamin Stein sold 14,600 shares of MiMedx Group stock. The stock was sold at an average price of $3.47, for a total transaction of $50,662.00.
MiMedx Group Stock Down 0.6 %
MiMedx Group stock opened at $3.44 on Friday. The firm has a market cap of $390.81 million, a price-to-earnings ratio of -13.76 and a beta of 1.75. The company has a debt-to-equity ratio of 586.91, a current ratio of 3.53 and a quick ratio of 3.17. MiMedx Group, Inc. has a fifty-two week low of $3.04 and a fifty-two week high of $8.69. The firm has a fifty day moving average price of $3.67 and a two-hundred day moving average price of $3.97.
MiMedx Group (NASDAQ:MDXG – Get Rating) last released its earnings results on Tuesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). The business had revenue of $66.88 million for the quarter, compared to analysts' expectations of $65.07 million. As a group, analysts forecast that MiMedx Group, Inc. will post -0.29 earnings per share for the current year.Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the stock. HC Wainwright decreased their price objective on shares of MiMedx Group from $8.50 to $8.00 and set a "buy" rating for the company in a report on Wednesday, September 7th. StockNews.com lowered shares of MiMedx Group from a "buy" rating to a "hold" rating in a research report on Friday, September 9th.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $41,000. Russell Investments Group Ltd. acquired a new position in shares of MiMedx Group during the second quarter valued at about $28,000. Spinnaker Investment Group LLC acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $47,000. Tiedemann Advisors LLC acquired a new position in shares of MiMedx Group during the first quarter valued at about $49,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of MiMedx Group during the first quarter valued at about $50,000. Institutional investors and hedge funds own 60.86% of the company's stock.
About MiMedx Group
(Get Rating)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Read More
- Get a free copy of the StockNews.com research report on MiMedx Group (MDXG)
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
MiMedx Group, Inc. (NASDAQ:MDXG – Get Rating) insider Robert Benjamin Stein sold 19,000 shares of the company's stock in a transaction on Monday, September 12th. The stock was sold at an average price of $3.44, for a total transaction of $65,360.00. Following the completion of the sale, the insider now owns 287,002 shares of the company's stock, valued at $987,286.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
米梅德克斯集團(納斯達克代碼:MDXG-GET Rating)內部人士羅伯特·本傑明·斯坦在9月12日星期一的一筆交易中出售了19,000股該公司股票。該股以3.44美元的平均價格出售,總成交金額為65,360.00美元。出售完成後,這位內部人士現在擁有該公司287,002股股票,價值987,286.88美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過以下鏈接獲得。
Robert Benjamin Stein also recently made the following trade(s):
羅伯特·本傑明·斯坦最近還進行了以下交易:
- On Friday, August 12th, Robert Benjamin Stein sold 8,503 shares of MiMedx Group stock. The stock was sold at an average price of $4.04, for a total transaction of $34,352.12.
- On Thursday, August 4th, Robert Benjamin Stein sold 19,500 shares of MiMedx Group stock. The stock was sold at an average price of $3.62, for a total transaction of $70,590.00.
- On Tuesday, June 28th, Robert Benjamin Stein sold 14,600 shares of MiMedx Group stock. The stock was sold at an average price of $3.47, for a total transaction of $50,662.00.
- 8月12日,星期五,羅伯特·本傑明·斯坦出售了8,503股MiMedx集團股票。該股以4.04美元的平均價格出售,總成交金額為34352.12美元。
- 8月4日,星期四,羅伯特·本傑明·斯坦出售了19,500股MiMedx集團股票。該股以3.62美元的平均價格出售,總成交金額為70,590.00美元。
- 6月28日,星期二,羅伯特·本傑明·斯坦出售了14,600股MiMedx集團股票。該股以3.47美元的平均價格出售,總成交金額為50,662.00美元。
MiMedx Group Stock Down 0.6 %
MiMedx集團股價下跌0.6%
MiMedx Group stock opened at $3.44 on Friday. The firm has a market cap of $390.81 million, a price-to-earnings ratio of -13.76 and a beta of 1.75. The company has a debt-to-equity ratio of 586.91, a current ratio of 3.53 and a quick ratio of 3.17. MiMedx Group, Inc. has a fifty-two week low of $3.04 and a fifty-two week high of $8.69. The firm has a fifty day moving average price of $3.67 and a two-hundred day moving average price of $3.97.
MiMedx Group股價上週五開盤報3.44美元。該公司的市值為3.9081億美元,市盈率為-13.76倍,貝塔係數為1.75。該公司的債務權益比為586.91,流動比率為3.53%,速動比率為3.17%。MiMedx Group,Inc.的股價為3.04美元,為52周低點,52周高點為8.69美元。該公司的50日移動均線價格為3.67美元,200日移動平均價格為3.97美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
A number of equities research analysts recently issued reports on the stock. HC Wainwright decreased their price objective on shares of MiMedx Group from $8.50 to $8.00 and set a "buy" rating for the company in a report on Wednesday, September 7th. StockNews.com lowered shares of MiMedx Group from a "buy" rating to a "hold" rating in a research report on Friday, September 9th.
一些股票研究分析師最近發佈了關於該股的報告。在9月7日星期三的一份報告中,HC Wainwright將MiMedx Group的股票目標價從8.50美元下調至8.00美元,併為該公司設定了“買入”評級。在9月9日星期五發布的一份研究報告中,StockNews.com將MiMedx Group的股票評級從買入下調至持有。
Institutional Inflows and Outflows
機構資金流入和流出
Large investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $41,000. Russell Investments Group Ltd. acquired a new position in shares of MiMedx Group during the second quarter valued at about $28,000. Spinnaker Investment Group LLC acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $47,000. Tiedemann Advisors LLC acquired a new position in shares of MiMedx Group during the first quarter valued at about $49,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of MiMedx Group during the first quarter valued at about $50,000. Institutional investors and hedge funds own 60.86% of the company's stock.
大型投資者最近對他們在該股的頭寸進行了調整。Point72 Hong Kong Ltd在第四季度收購了MiMedx Group的新股票頭寸,價值約41,000美元。羅素投資集團有限公司在第二季度收購了MiMedx集團價值約28,000美元的新股票頭寸。Spinnaker Investment Group LLC在第四季度收購了MiMedx Group的新股票頭寸,價值約4.7萬美元。Tiedemann Advisors LLC在第一季度收購了MiMedx集團新的股票頭寸,價值約4.9萬美元。最後,易方達基金管理有限公司在第一季度收購了MiMedx集團價值約5萬美元的新股票頭寸。機構投資者和對衝基金持有該公司60.86%的股票。
About MiMedx Group
關於MiMedx集團
(Get Rating)
(獲取評級)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
MiMedx Group,Inc.為醫療保健的各個部門開發和分銷同種異體胎盤組織移植。它利用其專利和專有的PURION工藝處理人類胎盤組織,以生產保留組織固有生物學特性和調節蛋白的同種異體移植物。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on MiMedx Group (MDXG)
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 免費獲取StockNews.com關於MiMedx集團的研究報告(MDXG)
- 沒有人告訴這三隻股票這是下跌的一週
- 有什麼辦法可以治癒Teladoc股票的問題嗎?
- 為什麼醫療產品製造商Repligen可能成為潛在收購對象
- 在10%的水平上,Arbor Realty Trust的股息值得嗎?
- 投資者應關注RF Industries
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受MiMedx集團日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收MiMedx集團和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧